Table 1 Clinical and demographic characteristics of 577 patients from 26 studies included in the systematic review
From: Effectiveness of rituximab in neuromyelitis optica: a meta-analysis
Reference (study) | Research type | Patient No. | Sex (F/M) | Age (year) | AQP4-Ab (+) (case) | Duration of disease (years/month) | Follow-up (years/month) |
|---|---|---|---|---|---|---|---|
Jacob [11] 2008 | Retrospective | 25 | 22/3 | 38(7–65) | 11 | 4.5(0.8–17)y | 19(6–40)m |
Jarius [14] 2008 | Retrospective | 4 | NC | 45(19–59) | 4 | NC | 62(33–144)m |
Pellkofer [16] 2011 | Prospective | 9 | 8/1 | 36.1(11.5) | 9 | 11(7.7)y | 29.6(14.5)m |
Gurdesh [2] 2011 | Retrospective | 23 | 21/2 | 37.1(14.6) | 15 | 114(13–266)m | 32.5(7–63)m |
Lindsey [26] 2012 | Retrospective | 8 | 7/1 | 37.6(14.4) | 4 | 65.1(53.7)m | 39.9(40.7)m |
Yang [20] 2013 | Retrospective | 3 | NC | 34.3(8.5) | 2 | 9.3(4)y | 12.7(0.6)m |
Ip [5] 2013 | Retrospective | 7 | 6/1 | 52(22–62) | 4 | 57(40–272)m | 24(1–42)m |
Ayzenberg [27] 2013 | Retrospective | 3 | 3/0 | 35(7.8) | 3 | 6.7(3.7)y | 14.7(15.1)m |
Gredler [28] 2013 | observational | 4 | 4/0 | 42.5(15.4) | 4 | 6.2(4.2)y | 3.1(2.1)y |
Chay [10] 2013 | Retrospective | 6 | 4/2 | 37.8(20.6) | 3 | NC | NC |
Longoni [25] 2014 | Retrospective | 5 | 4/1 | 13.7(2.7) | 5 | 3.2(0.3)y | 21.5(6.9)m |
Kim [23] 2015 | Retrospective | 100 | 92/8 | 43(11) | 94 | 11(5)y | 67(9–108)m |
Zephir [22] 2015 | Retrospective | 32 | 27/5 | 45(12.1) | 28 | 6.5(1–410)m | 28.7(21)m |
Weinfurtner [18] 2015 | Retrospective | 4 | 3/1 | 26.5(22.3) | 3 | 6.5(3.1)y | 6(1.2)y |
Jeong [29] 2015 | Retrospective | 55 | 50/5 | 42(15–68) | 52 | 41.7(2.1–231.5)m | 64.7(6.2–99.8)m |
Valentino [7] 2016 | Retrospective | 7 | 6/1 | 38.3(16.6) | 7 | NC | 59.4(29.7)m |
Annovazzi [1] 2016 | Retrospective | 76 | 64/9 | 46.5(12.5) | 53 | 6(7.2)y | 35.6(27)m |
Collongues [30] 2016 | Retrospective | 21 | 19/2 | 37.8(15.5) | 19 | 46.9(51.2)m | 31(18)m |
Zhang [31] 2017 | Case-control | 31 | 23/8 | 42.2(16.9) | 15 | 4.05(2.11)y | 27.45(11.68)m |
Nikoo [32]2017 | RCT | 33 | 29/4 | 35.33(8.98) | 13 | 6.23(4.29)y | > 12 m |
Evange. [17]2017 | Retrospective | 5 | 5/0 | 54(10.21) | 5 | 6.8(1.3)y | 6.6(0.9)y |
Cohen [33] 2017 | Prospective | 40 | 33/7 | 40.2(22–62) | 20 | 40(2–165)m | 2y |
Tallantyre [34] 2018 | Retrospective | 5 | 5/0 | 36.6(14.5) | 5 | 11.5(9.4)y | 3.5(0.2–8.9)y |
Yang [15] 2018 | Prospective | 20 | 19/1 | 40.7(11.4) | 10 | 11(0.2–240)m | 29(18–40)m |
Cabre [35] 2018 | Prospective | 32 | 30/2 | 39.9(12.1) | 20 | NC | 2y |
Li [21] 2018 | Retrospective | 19 | 16/3 | 34.8(13.7) | 17 | 3.4(3.4)y | 2.5(1.7)y |